Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 3Vipoma 2Somatostatinoma 2Neuroblastoma 2Neoplasms 2Insulinoma 2Glucagonoma 2Gastrinoma 2Colonic Neoplasms 2Carcinoma, Islet Cell 2Testicular Neoplasms 1Teratoma 1Stomach Neoplasms 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Lung Neoplasms 1Hepatoblastoma 1Gastrointestinal Stromal Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Gallbladder Neoplasms 1Familial ependymoma 1Fallopian Tube Neoplasms 1

Interventions

Everolimus 6Sunitinib 3Octreotide 3cabozantinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Injections 2Fluorouracil 2Capecitabine 2Bevacizumab 2recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1X-Rays 1Thalidomide 1Temozolomide 1Streptozocin 1Sorafenib 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Oxaliplatin × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡